Titration schedules in phase 3 trials of long acting insulin analogues incorporated individualization to allow the clinician to increase the dose to achieve optimal benefit without causing hypoglycaemia ( The oral obesity medications The oral GLP-1 based agents approved for obesity treatment deliver substantial weight loss
A study of 559 Blue Sky MD patients showed an average weight loss of 13% in just 12 weeks , or nearly 30 pounds in just 3 months, when combined with our medical weight loss program
Tirzepatide is FDA-approved and available now as Mounjaro (type 2 diabetes) and Zepbound (obesity)
GLP-1s are only one part of the weight loss equation, says Neha Agrawal, Pharm.D., AAHIVP, Director of Clinical Pharmacy Services at Legacy
What to Expect at Aspire MedSpa and Beauty Bar Choosing Aspire MedSpa and Beauty Bar means youll receive expert guidance from our compassionate team every step of the way
A 15 to 25% increase in IGF-1 above baseline indicates the peptide is working as intended